Pancreatic Polypeptide

Summary

Pancreatic Polypeptide (PP) is a 36-amino acid peptide hormone secreted by the F cells of the pancreatic islets in response to food intake. It is a member of the neuropeptide Y (NPY) family and plays a role in regulating appetite, energy homeostasis, and gastrointestinal function. Endogenous PP levels are reduced in obesity and elevated in anorexia nervosa. Exogenous administration has been explored as a potential treatment for obesity and metabolic disorders, though no approved therapeutic formulations currently exist.

Mechanism of Action

Binds Y4 receptors (and Y1, Y5 to lesser extent) in the hypothalamus, brainstem, and gastrointestinal tract to suppress appetite, slow gastric emptying, reduce pancreatic exocrine secretion, and decrease gallbladder motility. Acts as a satiety signal released postprandially by PP cells (F cells) of the pancreatic islets.

Routes of Administration

Goals & Uses

• Reduction of pancreatic exocrine secretionGastrointestinalModerate
• Biomarker for pancreatic neuroendocrine tumorsOncology / DiagnosticsHigh
• Appetite suppression / weight lossMetabolic / ObesityModerate
• Treatment of Prader-Willi syndrome hyperphagiaRare Disease / MetabolicLow
• Gastroparesis / gastric motility modulationGastrointestinalLow

Contraindications

• Hypersensitivity to pancreatic polypeptide or excipientsAllergyHigh
• Severe renal impairmentOrganModerateKidney function concerns

Adverse Effects

• HypoglycemiaMetabolicRareAbnormally low blood glucose
• Injection site reactionsLocalUncommon
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• Reduced gastric motilityGastrointestinalCommon

Drug Interactions

• Insulin / Hypoglycemic agentsLow
• Anticholinergic agentsLow

Population Constraints

• Pediatric populationsAgeRelative
• Patients with known PPomasOncologyRelative
• Patients with anorexia nervosaEating DisordersRelative
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionUnapprovedNo EMA-approved indication. Investigated under academic and early-phase clinical research.
• United StatesUnapprovedNo FDA-approved therapeutic product. Used as a research compound and endogenous biomarker in clinical diagnostics.
• United KingdomUnapprovedNo MHRA-approved therapeutic indication. Used as biomarker and research tool.

No approved therapeutic indication in any major jurisdiction. Pancreatic Polypeptide is used as a research and investigational compound. Endogenous PP is measured clinically as a biomarker for pancreatic endocrine function and neuroendocrine tumors (PPomas).

Evidence & Sources

No sources recorded yet.